The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Supplemental Application for Denosumab Goes to FDA

Supplemental Application for Denosumab Goes to FDA

October 25, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In early October, the U.S. Food and Drug Administration (FDA) accepted for review a supplemental biologics license application for denosumab (Prolia) to treat patients with glucocorticoid-induced osteoporosis. The application was submitted to the agency on July 28, 2017.1

You Might Also Like
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density
Also By This Author
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

In the Phase 3 study on which the application was based, the efficacy and safety of denosumab were evaluated and the treatment was compared with risedronate in patients receiving glucocorticoid treatment. The study was conducted in a randomized, double-blind, double-dummy, active-controlled format. Two study groups—patients who were already receiving and continuing with glucocorticoid therapy, and patients who had newly begun receiving glucocorticoid therapy—were evaluated to determine the percent change from baseline in lumbar spine and total hip bone mineral density (BMD) at Month 12.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study showed that in patients continuing glucocorticoid therapy, denosumab treatment led to greater BMD increases compared with risedronate-treated patients at both the lumbar spine (4.4% vs. 2.3%) and total hip (2.1% vs. 0.6%). In patients who had newly started glucocorticoid therapy, denosumab also led to greater BMD increases compared with risedronate-treated patients in both the lumbar spine (3.8% vs. 0.8%) and the total hip (1.7% vs. 0.2%).

Adverse reactions and serious adverse reactions were similar for both treatment groups and consistent with the known safety profile of denosumab. The Prescription Drug User Fee Act action date has been set for May 28, 2018.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Amgen. News release: FDA accepts supplemental biologics license application for Prolia (denosumab) in glucocorticoid-induced osteoporosis. 2017 Oct 9.

 

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: denosumab, FDA, Glucocorticoid-Induced Osteoporosis, Osteoporosis, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.